Back to search

Article

Liraglutide Use in A Real-World Setting: Patient Characteristics at Antidiabetic Treatment Initiation Modulate Cardiovascular Safety Outcomes

2020-09-04

Abstract excerpt

<title>Abstract</title> <p><bold>Background: </bold>Generation of real-world cardiovascular drug safety evidence in patients with type 2 diabetes (T2D) warrants robust methodology.<bold> </bold>Regulatory<bold> </bold>authorities are increasingly seeking to support their decision making through real-world evidence. At the time of marketing authorization, this study was required by regulatory authorities to furthe...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
cac65caf-f40e-5a8a-8060-694c733a5195
DOI
10.21203/rs.3.rs-66177/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Liraglutide Use in A Real-World Setting: Patient Characteristics at Antidiabetic Treatment Initiation Modulate Cardiovascular Safety OutcomesDOI 10.21203/rs.3.rs-66177/v1
RESEARCH PROTOCOL: Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitusSemantic proximity
Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort studySemantic proximity
Cardiovascular Outcomes of Tirzepatide vs Semaglutide in Obesity Without Type 2 Diabetes: A Matched Cohort StudySemantic proximity
CETP and SGLT2 inhibitor combination therapy improves glycemic controlSemantic proximity
Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Large-scale, Multinational, Federated Analysis of the LEGEND-T2DM StudySemantic proximity
Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A 2x2 Factorial Mendelian Randomization StudySemantic proximity
Emulating randomized controlled trials of long-acting insulins and cardiovascular events using real-world data for patients with type 2 diabetesSemantic proximity
Derivation and validation of a type 2 diabetes treatment selection algorithm for SGLT2-inhibitor and DPP4-inhibitor therapies based on glucose-lowering efficacy: cohort study using trial and routine clinical dataSemantic proximity
Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease Risk: Findings from Real-World Data using AI-Powered OutcomesSemantic proximity
Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes: An Umbrella ReviewSemantic proximity
Effect of GLP-1R rs2254336 and rs3765467 polymorphisms on gastrointestinal adverse reactions in type 2 diabetes patients treated with liraglutide.Semantic proximity
Cardiorenal outcomes of tirzepatide versus semaglutide in adults with type 2 diabetes and chronic kidney disease: a target trial emulation in the TriNetX Global Collaborative NetworkSemantic proximity
Select a neighboring publication to make it the new centre.